Cardinal Health CAH is increasingly positioning itself as a foundational layer of the U.S. healthcare system, leveraging scale, operational reliability and integrated capabilities to deepen its role across pharmaceutical distribution, specialty care and advanced logistics. Management’s commentary in the third quarter of fiscal 2026 suggests the company is evolving beyond a distributor into a critical healthcare infrastructure partner.
At the center of this positioning is Cardinal Health’s vast distribution network, which supports tens of thousands of healthcare locations across the United States, including hospitals, pharmacies, physician offices and specialty clinics. The company’s Pharmaceutical & Specialty Solutions segment alone contributed approximately $61 billion to quarterly revenues, underscoring the scale and centrality of its operations to healthcare delivery.
Cardinal Health’s influence increasingly spans multiple layers of the care continuum. Beyond traditional pharmaceutical distribution, the company has expanded into specialty drug distribution, physician-facing MSO platforms, biopharma services, logistics and nuclear medicine.
Specialty Alliance networks in oncology, rheumatology and urology deepen provider relationships, while Sonexus hub services and 3PL capabilities support manufacturer commercialization and patient access. Nuclear and Precision Health Solutions further broadens the company’s role in high-value diagnostic and treatment pathways.
Operational reliability has also become a differentiator. Management has emphasized Cardinal Health’s ability to maintain service continuity during periods of industry-wide supply-chain disruption and drug shortages. The majority of its manufacturing facilities are based in the United States, reinforcing its importance as a trusted intermediary within healthcare. This reliability strengthens its relationship with both providers and manufacturers, especially as supply chains become more complex.
Cardinal Health is driving greater integration across healthcare supply chains. Its “specialty flywheel” strategy increasingly connects manufacturers, providers and patients through a unified ecosystem of distribution, access and support services. This integration enhances visibility, improves efficiency and creates cross-segment growth opportunities.
CAH appears to be transitioning from a logistics provider to a strategic backbone of U.S. healthcare infrastructure, with scale and ecosystem integration reinforcing long-term relevance.
Peer Updates
Hims & Hers Health HIMS is increasingly reshaping U.S. healthcare infrastructure by building a consumer-first, technology-enabled care platform that bypasses many traditional friction points in care delivery. Hims & Hers is expanding access to treatments across weight loss, testosterone, menopause and labs through an integrated ecosystem of providers, pharmacies and AI-enabled tools.
Management emphasized that Hims & Hers now supports nearly 2.6 million subscribers and tens of millions of annual patient touchpoints, using AI, at-home diagnostics and digital care pathways to improve access and personalization. By partnering with pharma companies and broadening GLP-1 access, Hims & Hers is increasingly acting as a scalable digital front door to healthcare.
LifeMD LFMD is also redefining healthcare infrastructure by creating an integrated virtual care ecosystem that combines telehealth, pharmacy, diagnostics, insurance integration and AI-driven workflows. LifeMD has strong presence with its 50-state affiliated medical group, in-house pharmacy and national lab capabilities, positioning the platform as more than a point-solution telehealth provider.
LFMD is expanding access to weight management, women’s health and chronic care while using AI to improve provider productivity and personalize treatment. With insurance coverage expected to expand to 230 million covered lives, LifeMD is helping shift care delivery toward a more connected, lower-friction and digitally coordinated healthcare infrastructure.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have lost 2.8% so far this year compared with the industry’s 10.3% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 16.93, above the industry average. It is also higher than its five-year median of 13.67. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report
LifeMD, Inc. (LFMD): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).